CoChat
Sign Up
Cited by 14Ion channel regulation and functionIon Transport and Channel RegulationErythrocyte Function and Pathophysiology

The DOI matches its Crossref record.

K + Channels as Therapeutic Targets in Oncology

Stühmer, Walter, Pardo, Luis A·2010·Future Medicinal Chemistry
DOI 10.4155/fmc.10.24
Open this paper in CoChat — free account

Abstract

Ion channels are involved in a variety of tumors. In particular, potassium channels are expressed abnormally in many cancer types, where their pharmacologic manipulation impairs tumor progression. Since this group of molecules has been successfully targeted for decades in other therapeutic areas, there is a significant body of knowledge on the pharmacology of potassium channels. Several groups of potassium channels with defined molecular identities have been proposed as candidates for therapeutic intervention. The strategies put forward range from classical small molecule blockade to gene therapy approaches, and include the use of potassium channels as targets for adjuvant therapy. We will discuss the reasons for these proposals and explore possible future developments.

Overview

Integrity signals

Registry

Crossref · 10.4155/fmc.10.24

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Modulating the Vm of malign tissues by adjusting the activities of various ion channels/transporters may provide a convenient clinical approach.

    “Considering the vast array of therapeutic drugs that target ion channels (Sontheimer, 2008; Stuhmer and Pardo, 2010; D'amico et al., 2013; Djamgoz and Onkal, 2013), modulating the Vm of malign tissues by adjusting the activities of varies ion channels/transporters may provide a convenient clinical approach.”

    From Membrane potential and cancer progression (2013) · cites this paper as Stuhmer and Pardo, 2010

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 138

  1. 10.1038/nature01580 · DOI
  2. 10.1126/science.1116269 · DOI
  3. 10.1124/pr.57.4.10 · DOI
  4. 10.1002/j.1460-2075.1988.tb02917.x · DOI
  5. 10.1126/science.2441471 · DOI
  6. 10.1016/j.ceca.2007.04.004 · DOI
  7. 10.1124/pr.57.4.9 · DOI
  8. 10.1007/s12013-007-0007-8 · DOI
  9. 10.1016/j.tins.2007.08.003 · DOI
  10. 10.2174/1381612054546824 · DOI
  11. 10.1038/nrd2983 · DOI
  12. 10.1159/000055328 · DOI
  13. 10.1097/MPA.0b013e3181a56ebf · DOI
  14. 10.1159/000227810 · DOI
  15. 10.1016/j.lungcan.2009.11.002 · DOI
  16. 10.1158/1055-9965.EPI-07-2518 · DOI
  17. 10.1093/hmg/ddm216 · DOI
  18. 10.1002/jcp.1041650121 · DOI · Paper page
  19. 10.1016/S0304-3835(02)00348-8 · DOI · Paper page
  20. 10.1007/s00424-003-1077-0 · DOI
  21. 10.1006/bbrc.2000.3790 · DOI · Paper page
  22. 10.5483/BMBRep.2009.42.8.535 · DOI
  23. Abdul M , HooseinN. Voltage-gated potassium ion channels in colon cancer.Oncol. Rep.9(5), 961–964 (2002).
  24. 10.1007/s00232-006-0065-7 · DOI
  25. 10.1034/j.1600-0714.2003.00197.x · DOI
  26. 10.1111/j.1600-0714.2004.00236.x · DOI
  27. Suzuki T , TakimotoK. Selective expression of hERG and Kv2 channels influences proliferation of uterine cancer cells. Int. J. Oncol.25(1), 153–159 (2004).
  28. 10.4161/cbt.4.12.2175 · DOI
  29. 10.1016/j.ygyno.2006.08.033 · DOI
  30. 10.1016/S0304-3940(03)00562-7 · DOI
  31. 10.1007/s00232-007-9080-6 · DOI
  32. 10.2174/157489207782497181 · DOI
  33. 10.1007/s10555-006-9017-z · DOI
  34. 10.1016/j.cdp.2006.06.002 · DOI
  35. 10.1007/s00232-005-0776-1 · DOI · Paper page
  36. 10.2174/157489207782497244 · DOI
  37. 10.2174/156800909790192400 · DOI
  38. Abdul M , SantoA, HooseinN. Activity of potassium channel-blockers in breast cancer.Anticancer Res.23(4), 3347–3351 (2003).
  39. 10.1007/s00280-004-0960-5 · DOI
  40. 10.1016/j.pbiomolbio.2008.10.006 · DOI
  41. 10.1113/jphysiol.1995.sp021065 · DOI
  42. 10.1054/bjoc.2000.1497 · DOI
  43. 10.1038/sj.leu.2402572 · DOI
  44. 10.1074/jbc.M200592200 · DOI
  45. 10.4161/cbt.7.1.5126 · DOI
  46. 10.1016/j.cellsig.2009.09.010 · DOI
  47. 10.1074/jbc.M210789200 · DOI
  48. 10.1074/jbc.273.42.27231 · DOI
  49. 10.1128/MCB.00304-08 · DOI
  50. 10.1007/s10620-009-0834-0 · DOI
  51. 10.1002/jcp.20748 · DOI
  52. 10.1002/jso.20891 · DOI
  53. Bianchi L , WibleB, ArcangeliAet al. hERG encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? Cancer Res. 58(4), 815–822 (1998).
  54. Roy J , VantolB, CowleyEA, BlayJ, LinsdellP. Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line mcf-7. Oncol Rep.19(6), 1511–1516 (2008).
  55. 10.1016/j.ejphar.2007.10.008 · DOI
  56. 10.1091/mbc.e04-10-0940 · DOI
  57. 10.1182/blood-2006-02-003772 · DOI
  58. 10.1038/sj.bjc.6602775 · DOI
  59. 10.1006/bbrc.2001.5464 · DOI
  60. 10.1002/jcp.21015 · DOI
  61. Wang H , ZhangY, CaoLet al. hERG K+ channel, a regulator of tumor cell apoptosis and proliferation. Cancer Res. 62(17), 4843–4848 (2002).
  62. 10.1007/s11255-008-9459-z · DOI
  63. 10.1016/j.pbiomolbio.2009.01.002 · DOI
  64. 10.1152/ajpcell.00633.2008 · DOI
  65. 10.1096/fj.05-5350fje · DOI
  66. 10.4161/cbt.4.3.1500 · DOI
  67. 10.1016/j.pharmthera.2008.05.009 · DOI
  68. 10.1016/j.neuroscience.2008.05.019 · DOI
  69. 10.1016/S0014-5793(98)00973-9 · DOI
  70. 10.1111/j.1469-7793.1998.317be.x · DOI
  71. 10.1152/ajpcell.00089.2007 · DOI
  72. 10.1093/emboj/18.20.5540 · DOI · Paper page
  73. 10.1158/0008-5472.CAN-08-2036 · DOI
  74. 10.1186/1476-4598-5-41 · DOI
  75. 10.1016/j.exphem.2006.06.020 · DOI
  76. Murata H , TajimaN, NagashimaYet al. Von hippel-lindau tumor suppressor protein transforms human neuroblastoma cells into functional neuron-like cells. Cancer Res. 62(23), 7004–7011 (2002).
  77. Ouadid-Ahidouch H , Le Bourhis X, Roudbaraki M, Toillon RA, Delcourt P, Prevarskaya N. Changes in the K+ current-density of MCF-7 cells during progression through the cell cycle: Possible involvement of a human-ether-a-go-go K+ channel. Receptors Channels7(5), 345–356 (2001).
  78. 10.1096/fj.06-6200com · DOI
  79. 10.1007/s12032-007-0015-y · DOI
  80. 10.3748/wjg.v13.i8.1257 · DOI
  81. 10.1186/1476-4598-5-42 · DOI
  82. 10.1007/s002329900563 · DOI
  83. Weber C , Mello De Queiroz F, Downie B, Sukow A, Stühmer W, Pardo LA. Silencing the activity and proliferative properties of the human Eag1 potassium channel by RNAi. J. Biol. Chem.281, 13033–13037 (2006).
  84. 10.1158/1078-0432.CCR-06-1940 · DOI
  85. 10.1016/j.lfs.2007.05.014 · DOI
  86. 10.1007/s10620-007-0116-7 · DOI
  87. 10.1007/s00424-008-0451-3 · DOI
  88. 10.1074/jbc.M703758200 · DOI
  89. 10.1016/j.neulet.2004.07.001 · DOI
  90. 10.1016/j.yexcr.2009.11.008 · DOI
  91. 10.1074/jbc.M801830200 · DOI
  92. 10.1186/1476-4598-9-18 · DOI
  93. 10.1007/s00232-001-0181-3 · DOI
  94. 10.1158/0008-5472.CAN-07-0107 · DOI
  95. 10.1073/pnas.0505909103 · DOI
  96. 10.1016/j.febslet.2006.03.062 · DOI
  97. 10.1113/jphysiol.1992.sp018938 · DOI · Paper page
  98. 10.2174/092986707780831186 · DOI
  99. 10.1007/s00424-007-0258-7 · DOI
  100. 10.1038/sj.onc.1210308 · DOI
  101. 10.1152/ajpcell.00354.2008 · DOI
  102. Nilius B , SchwarzG, DroogmansG. Control of intracellular calcium by membrane potential in human melanoma cells.Am. J. Physiol.265(6, 1), C1501–1510 (1993). · DOI
  103. 10.1038/onc.2009.25 · DOI
  104. 10.1016/S0014-2999(03)01825-9 · DOI
  105. 10.1007/s002329900066 · DOI
  106. 10.1159/000095135 · DOI
  107. 10.1113/jphysiol.2005.096818 · DOI
  108. 10.1085/jgp.113.1.81 · DOI
  109. 10.1074/jbc.M208914200 · DOI
  110. 10.1016/j.ceca.2009.03.014 · DOI
  111. 10.1186/1471-2407-9-258 · DOI
  112. 10.1038/sj.onc.1210036 · DOI
  113. 10.1002/glia.20364 · DOI
  114. 10.1152/jn.2001.85.2.790 · DOI
  115. 10.3181/0711-MR-308 · DOI · Paper page
  116. 10.1007/s00424-003-1012-4 · DOI
  117. 10.1007/s00424-008-0452-2 · DOI
  118. 10.1159/000016309 · DOI
  119. 10.1124/jpet.301.3.838 · DOI
  120. 10.1186/1476-4598-6-22 · DOI
  121. 10.1358/dnp.2003.16.5.878815 · DOI
  122. 10.1158/1078-0432.CCR-07-1826 · DOI
  123. 10.1016/j.ejphar.2008.10.056 · DOI
  124. 10.4161/cbt.8.20.9490 · DOI
  125. 10.1002/jcp.1041620202 · DOI · Paper page
  126. 10.1093/carcin/bgp034 · DOI
  127. 10.1111/j.1440-1681.1998.tb02172.x · DOI
  128. Zhou Q , KwanHY, ChanHC, JiangJL, TamSC, YaoX. Blockage of voltage-gated K+ channels inhibits adhesion and proliferation of hepatocarcinoma cells. Int. J. Mol. Med.11(2), 261–266 (2003).
  129. 10.1016/j.brainres.2008.06.046 · DOI
  130. 10.1016/j.brainres.2007.05.053 · DOI
  131. 10.1016/j.brainres.2007.01.133 · DOI
  132. 10.1007/s00424-004-1255-8 · DOI
  133. 10.1111/j.1600-0463.2004.apm1120905.x · DOI
  134. 10.1016/S1535-6108(03)00054-0 · DOI
  135. 10.1007/s00428-007-0545-x · DOI
  136. 10.1007/s11060-008-9517-5 · DOI
  137. 10.1073/pnas.1232448100 · DOI
  138. 10.1158/0008-5472.CAN-07-5163 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Stühmer, W., & Pardo, L. A.
Affiliations
Max Planck Institute of Experimental Medicine (DE)
ORCID
Venue
Future Medicinal Chemistry
Publisher
Informa UK Limited
Published
2010-05
Volume
2
Issue
5
Pages
745-755
ISSN
  • 1756-8919 (ISSN-L)
  • 1756-8927
DOI
10.4155/fmc.10.24
OpenAlex
W2038338230
Cited by
14
References
0
Citations by year
2024: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2016: 1 · 2014: 1 · 2013: 3 · 2012: 2
FWCI
0.22
Type
journal article
Language
en
Open access
closed
Locations
  • Future Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
  • Max Planck Institute for Plasma Physics (submittedVersion)
  • MPG.PuRe (Max Planck Society) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
  • Health Sciences › Medicine › Physiology (medical) › Erythrocyte Function and Pathophysiology
Keywords
potassium channels, cancer therapy, potassium channel blockers, small molecule inhibitors, gene therapy, adjuvant therapy, therapeutic target
MeSH terms
Animals, Antineoplastic Agents, Humans, Neoplasms, Potassium Channels, Gene Expression Regulation, Neoplastic, Potassium Channel Blockers, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review